Medtronic plc — Director's Dealing 2017

Aug 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Medtronic plc (MDT)
CIK: 0001613103
Period of Report: 2017-07-31

Reporting Person: HAKAMI HOOMAN (EVP & Group President Diabetes)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-07-31	Ordinary Shares	A	9528	—	Acquired	65473	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-31	Stock Option (Right to Buy)	$83.97	A	38109	Acquired	2027-07-31	Ordinary Shares (38109)	Direct
2017-07-31	Stock Option (Right to Buy)	$83.97	A	1191	Acquired	2027-07-31	Ordinary Shares (1191)	Direct

Footnotes

F1: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee.

F2: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.